Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
29.69
-0.01 (-0.03%)
Oct 12, 2026, 4:00 PM EDT - Market closed
Caris Life Sciences Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Caris Life Sciences stock has a consensus rating of "Buy" and an average price target of $30.38. The average 1-year stock price forecast is 2.32% higher than the current stock price, while the lowest is $22 (-25.90%) and the highest is $38 (+27.99%).
Price Target: $30.38 (+2.32%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Caris Life Sciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 9 | 9 | 9 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 3 | 3 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $23 → $35 | Buy | Maintains | $23 → $35 | +17.88% | Oct 9, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $27 → $35 | Buy | Maintains | $27 → $35 | +17.88% | Sep 21, 2026 |
Unknown Analyst UBS No rating | UBS | Hold Initiates $28 | Hold | Initiates | $28 | -5.69% | Sep 9, 2026 |
| BTIG | BTIG | Buy Reiterates $32 → $33 | Buy | Reiterates | $32 → $33 | +11.15% | Aug 7, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $25 | Buy | Maintains | $25 | -15.80% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
1.03B
from 812.03M
Increased by 26.75%
Revenue Next Year
1.23B
from 1.03B
Increased by 19.16%
EPS This Year
0.14
from -0.41
EPS Next Year
0.37
from 0.14
Increased by 170.41%
EPS and Forward PE are based on non-GAAP adjusted numbers.